Loading...
Loading...
QLGN| Name | Value |
|---|---|
| Revenues | 7,943.4K |
| Cost of Revenue | 5,588.8K |
| Gross Profit | 2,354.6K |
| Operating Expense | 2,778.4K |
| Operating I/L | -2,778.4K |
| Other Income/Expense | -456.7K |
| Interest Income | 0.0K |
| Pretax | -3,235.0K |
| Income Tax Expense | 421.5K |
| Net Income/Loss | -3,656.5K |
Qualigen Therapeutics, Inc. is a biotechnology company specializing in the development of innovative therapeutic products for cancer and infectious diseases. Its revenue streams are primarily derived from the sale of its FastPack rapid diagnostic testing system. The company's product pipeline includes QN-302 for pancreatic ductal adenocarcinoma, QN-247, a DNA coated gold nanoparticle cancer drug candidate, RAS-F, a small-molecule RAS oncogene protein-protein inhibitor, and the STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood.
